VIR Q4 2022 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$49M-93.9% YoY

Gross Profit

-$112M-226.2% margin

Operating Income

-$151M-304.6% margin

Net Income

-$102M-205.6% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-86.8%

Cash Flow

Operating Cash Flow

$35M

Free Cash Flow

$23M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.8B

Total Liabilities

$724M

Stockholders' Equity

$2.1B

Cash & Equivalents

$849M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$49M	$813M	-93.9%
Gross Profit	-$112M	$628M	-117.8%
Operating Income	-$151M	$572M	-126.3%
Net Income	-$102M	$525M	-119.3%

Revenue Segments

Collaboration Revenue

$22M99%

Contract Revenue

$180,0001%